Patents by Inventor Guoqing Cao

Guoqing Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11000518
    Abstract: A combination of a VEGFR inhibitor and a PARP inhibitor is described. In particular, this combination can be used in the preparation of a medicament for treating gastric cancer.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: May 11, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Jiahua Jiang, Guoqing Cao, Changyong Yang, Lianshan Zhang, Jianjun Zou, Piaoyang Sun
  • Publication number: 20210030736
    Abstract: This application describes a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor is described.
    Type: Application
    Filed: May 17, 2018
    Publication date: February 4, 2021
    Inventors: Ke MA, Guoqing CAO, Changyong YANG, Lianshan ZHANG
  • Publication number: 20210009706
    Abstract: The present invention provides an anti-CD27 antibody, an antigen-binding fragment thereof, and a medical use thereof. Specifically, the present invention provides a human antibody comprising the CDR region of the anti-CD27 antibody, and a pharmaceutical composition comprising the human anti-CD27 antibody and an antigen-binding fragment thereof, and a use thereof as an anticancer drug. In particular, the invention provides a human anti-CD27 antibody and a use thereof in the preparation of a drug for the treatment of CD27-mediated diseases or disorders.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 14, 2021
    Inventors: Hao Huang, Yan Fang, Zhen Yan, Ruijun Shi, Jiahua Jiang, Guoqing Cao, Lianshan Zhang
  • Publication number: 20200399375
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Application
    Filed: August 7, 2020
    Publication date: December 24, 2020
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • Publication number: 20200368309
    Abstract: Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description.
    Type: Application
    Filed: December 5, 2018
    Publication date: November 26, 2020
    Inventors: Xiaoxing HUANG, Guoqing CAO, Changyong YANG, Lianshan ZHANG
  • Patent number: 10815304
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 27, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • Publication number: 20200148778
    Abstract: Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composition including the human anti-CD40 antibody and the antigen binding fragment thereof, and an application thereof as an anti-cancer drug. In particular, provided are a humanized anti-CD40 antibody, and an application thereof in preparation of a drug to treat a CD40-mediated disease or disorder.
    Type: Application
    Filed: May 31, 2018
    Publication date: May 14, 2020
    Inventors: Shude Yan, Jiahua Jiang, Qiyue Hu, Lianshan Zhang, Guoqing Cao, Xueming Qian, Fei Teng
  • Publication number: 20200131263
    Abstract: Provided are an anti-GITR antibody, an antigen-binding fragment thereof, and pharmaceutical uses thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR of the anti-GITR antibody, a pharmaceutical composition containing the anti-GITR antibody or the antigen-binding fragment thereof, and use of the anti-GITR antibody in preparation of an anti-cancer drug. In particular, provided is a humanized anti-GITR antibody, and its use in the preparation of drugs for treating GITR-mediated diseases or disorders.
    Type: Application
    Filed: June 29, 2018
    Publication date: April 30, 2020
    Inventors: Shude YAN, Jiahua JIANG, Hao HUANG, Lianshan ZHANG, Guoqing CAO
  • Publication number: 20200054764
    Abstract: The medical use of an anti-c Met antibody-cytotoxic drug conjugate is described. In particular, an anti-c-Met antibody, an antigen-binding fragment thereof, a chimeric antibody and a humanized antibody containing the anti-c-Met antibody CDRs, and an antibody-cytotoxic drug conjugate thereof or a pharmaceutically acceptable salt or solvate thereof are described. Also described are the use of a pharmaceutical composition containing the humanized anti-c-Met antibody, the antigen-binding fragment thereof, the antibody-cytotoxic drug conjugate thereof, or the pharmaceutically acceptable salt or solvate thereof as an anti-hepatoma drug.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 20, 2020
    Inventors: Xing SUN, Guoqing CAO, Mi TANG, Jiahua JIANG, Changyong YANG, Lianshan ZHANG
  • Publication number: 20200054594
    Abstract: Provided are uses of the combination of a ? opioid receptor (MOR) agonist and a ? opioid receptor (KOR) agonist in the preparation of drugs for relieving and/or treating pain. The MOR agonist is selected from the compound represented in formula (I), or a tautomer, mesomer, racemate, enantiomer or diastereomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition containing the MOR agonist and the KOR agonist.
    Type: Application
    Filed: April 13, 2018
    Publication date: February 20, 2020
    Inventors: Zhuolu NIU, Guoqing CAO, Changyong YANG, Lianshan ZHANG
  • Publication number: 20200040078
    Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.
    Type: Application
    Filed: October 9, 2017
    Publication date: February 6, 2020
    Inventors: Xing SUN, Guoqing CAO, Changyong YANG, Lianshan ZHANG, Yong GUO
  • Publication number: 20190358212
    Abstract: Uses of an EGFR/HER2 inhibitor combined with a pyrimidine-type anti-metabolic drug are provided. Specifically, uses of an EGFR/HER2 receptor tyrosine kinase inhibitor combined with pyrimidine-type anti-metabolic drug in the preparation of drugs for treating cancers are provided.
    Type: Application
    Filed: January 19, 2018
    Publication date: November 28, 2019
    Inventors: Jianjun ZOU, Guoqing CAO, Xiaoyu ZHU
  • Publication number: 20190309069
    Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.
    Type: Application
    Filed: May 30, 2019
    Publication date: October 10, 2019
    Inventors: Jijun YUAN, Xiangdong QU, Jufang LIN, Xin YE, Guoqing CAO, Weikang TAO, Lianshan ZHANG, Lei ZHANG, Li YANG
  • Publication number: 20190275021
    Abstract: A combination of a VEGFR inhibitor and a PARP inhibitor is described. In particular, this combination can be used in the preparation of a medicament for treating gastric cancer.
    Type: Application
    Filed: November 30, 2017
    Publication date: September 12, 2019
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Jiahua JIANG, Guoqing CAO, Changyong YANG, Lianshan ZHANG, Jianjun ZOU, Piaoyang SUN
  • Publication number: 20190224189
    Abstract: Provided is a method of treating cancer with a tyrosine-kinase inhibitor. In particular, provided is a method of treating cancer containing a mutated epidermal growth factor receptor (EGFR) with compound A, or a pharmaceutically acceptable salt thereof, preferably a maleate or dimaleate salt of compound A.
    Type: Application
    Filed: September 22, 2017
    Publication date: July 25, 2019
    Inventors: Jianjun ZOU, Yaling HUANG, Tonghuan HU, Xiaoyu ZHU, Jun FENG, Changyong YANG, Chen ZONG, Guoqing CAO
  • Publication number: 20190225698
    Abstract: An anti-CD27 antibody, an antigen-binding fragment thereof, and a medical use of the same are described. Further, provided are a chimeric antibody comprising a CDR of the anti-CD27 antibody, a humanized antibody, a pharmaceutical composition comprising a human anti-CD27 antibody or an antigen-binding fragment thereof, and use of the same as an anti-cancer drug. The present invention particularly relates to a human anti-CD27 antibody and use thereof in preparing a drug for treating a CD27-mediated disease or disorder.
    Type: Application
    Filed: September 28, 2017
    Publication date: July 25, 2019
    Inventors: Shude YAN, Jiahua JIANG, Lianshan ZHANG, Guoqing CAO
  • Patent number: 10344090
    Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: July 9, 2019
    Assignees: Shanghai Hangrui Pharmaceutical Co., Ltd., Jiangsu Hangrui Medicine Co., Ltd.
    Inventors: Jijun Yuan, Xiangdong Qu, Jufang Lin, Xin Ye, Guoqing Cao, Weikang Tao, Lianshan Zhang, Lei Zhang, Li Yang
  • Patent number: 10206980
    Abstract: Provided is an IL-15 heterodimeric protein, such as an IL-15/IL-15R? heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15R? or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a “Knob-into-Hole” mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: February 19, 2019
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiangdong Qu, Xin Ye, Jijun Yuan, Lei Zhang, Kan Chen, Lianshan Zhang, Guoqing Cao, Zhibin Xu, Weikang Tao
  • Publication number: 20180334504
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 22, 2018
    Applicants: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiangdong QU, Qiyue HU, Shaoyu XU, Dongbing CUI, Houcong JIN, Weikang TAO, Lianshan ZHANG, Guoqing CAO, Piaoyang SUN
  • Patent number: 9862765
    Abstract: Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: January 9, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Lianshan Zhang, Jiajian Liu, Guoqing Cao, Piaoyang Sun